Vera Therapeutics, Inc. (NASDAQ:VERA) · earnings preview
Quarter
Q3
EPS estimate to actual
-$1.63
Revenue estimate to actual
$3.5M
At a glance
Key takeaways
01Vera Therapeutics will report Q3 2026 earnings on November 4 after market close, with analysts expecting a loss of $1.63 per share compared to breakeven a year ago.
02Revenue is projected to reach $3.5M, representing growth from the prior year quarter, though the company continues to report significant losses.
03The stock trades at $30.74 with a $2.9B market capitalization despite recent quarters showing losses ranging from $1.39 to $1.69 per share.
04Recent earnings performance shows volatility, with Q2 beating estimates by 4.4% but Q1 missing by 25.2%, suggesting inconsistent execution.
Earnings Results
Vera Therapeutics, Inc. (NASDAQ:VERA) is scheduled to report its Q3 earnings results on November 04, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $-1.63, below the $0.00 reported in the same quarter last year. Revenue is expected to come in at $3.5M, up from a year ago.
Company Overview
The stock currently trades at $30.74 with a market capitalization of $2.9B.
Ahead of Vera Therapeutics, Inc.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Vera Therapeutics, Inc. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.